Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NKTX
- Price
- 1.57
- Stock movement up
- +0.04 (2.94%)
- Company name
- Nkarta Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 111.15M
- Ent value
- 155.35M
- Price/Sales
- 10.54
- Price/Book
- 0.26
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -80.46%
- 3 year return
- -49.25%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NKTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 10.54 |
| Price to Book | 0.26 |
| EV to Sales | 14.74 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 70.57M |
| EPS (TTM) | -1.50 |
| FCF per share (TTM) | -1.47 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.54M |
| Gross profit (TTM) | 3.77M |
| Operating income (TTM) | -128.46M |
| Net income (TTM) | -110.61M |
| EPS (TTM) | -1.50 |
| EPS (1y forward) | -1.85 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 35.80% |
| Operating margin (TTM) | -1218.52% |
| Profit margin (TTM) | -1049.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 56.96M |
| Net receivables | 0.00 |
| Total current assets | 290.15M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 532.03M |
| Accounts payable | 1.94M |
| Short/Current long term debt | 85.45M |
| Total current liabilities | 22.47M |
| Total liabilities | 101.16M |
| Shareholder's equity | 430.87M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -98.30M |
| Capital expenditures (TTM) | 10.11M |
| Free cash flow (TTM) | -108.41M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.67% |
| Return on Assets | -20.79% |
| Return on Invested Capital | -25.27% |
| Cash Return on Invested Capital | -24.77% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.53 |
| Daily high | 1.64 |
| Daily low | 1.48 |
| Daily Volume | 1.18M |
| All-time high | 75.62 |
| 1y analyst estimate | 15.83 |
| Beta | 0.87 |
| EPS (TTM) | -1.50 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| NKTX | S&P500 | |
| Current price drop from All-time high | -97.92% | -12.89% |
| Highest price drop | -98.27% | -56.47% |
| Date of highest drop | 2 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -76.85% | -11.07% |
| Avg time to new high | 150 days | 12 days |
| Max time to new high | 1080 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
111.15M
Marketcap category
Small-cap
Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Employees
159
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page